Tripelennamine

This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Tripelennamine" – news · newspapers · books · scholar · JSTOR (August 2017) (Learn how and when to remove this message)

Tripelennamine

Clinical data
Trade names	Pyribenzamine
AHFS/Drugs.com	Multum Consumer Information
MedlinePlus	a601044
Routes of administration	Oral, intravenous
ATC code	D04AA04 (WHO) R06AC04 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Metabolism	Hepatic hydroxylation and glucuronidation
Elimination half-life	4–6 hours[1]
Excretion	Renal
Identifiers
IUPAC name N,N-dimethyl-N-(phenylmethyl)-N-pyridin-2-ylethane-1,2-diamine
CAS Number	91-81-6 Y 154-69-8 (monohydrochloride) 22306-05-4 (hydrochloride) 57116-36-6 (maleate) 6138-56-3 (citrate)
PubChem CID	5587
IUPHAR/BPS	7318
DrugBank	DB00792 Y
ChemSpider	5385 Y
UNII	3C5ORO99TY
KEGG	D08645 Y
ChEMBL	ChEMBL1241 Y
CompTox Dashboard (EPA)	DTXSID8023717
ECHA InfoCard	100.001.910
Chemical and physical data
Formula	C16H21N3
Molar mass	255.365 g·mol−1
3D model (JSmol)	Interactive image
SMILES CN(C)CCN(CC1=CC=CC=C1)C2=NC=CC=C2
InChI InChI=1S/C16H21N3/c1-18(2)12-13-19(16-10-6-7-11-17-16)14-15-8-4-3-5-9-15/h3-11H,12-14H2,1-2H3 Y Key:UFLGIAIHIAPJJC-UHFFFAOYSA-N Y
(verify)

Tripelennamine, sold under the brand name Pyribenzamine by Novartis, is a drug that is used as an antipruritic and first-generation antihistamine. It can be used in the treatment of asthma, hay fever, rhinitis, and urticaria, but is now less common as it has been replaced by newer antihistamines. The drug was patented at CIBA, which merged with Geigy into Ciba-Geigy, and eventually becoming Novartis.